Alkermes
Price & Volume
Stats
See more52W Range | $22.90-$36.45 |
Market Cap | $5.7B |
Shares Short | 10M |
Financials
See moreRevenue (12 Mos) | $1.5B |
Revenue Growth (YoY) | 13.9% |
Gross Profit (12 Mos) | $1.3B |
Diluted EPS | $2.20 |
News
See moreYahoo Finance • 11 days ago
Alkermes: Q4 Earnings Snapshot
Yahoo Finance • 6 months ago
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
Yahoo Finance • 6 months ago
We Ran A Stock Scan For Earnings Growth And Alkermes (NASDAQ:ALKS) Passed With Ease
Yahoo Finance • 10 months ago
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
About
CEO | Mr. Richard F. Pops |
CFO | Mr. Iain Michael Brown |
Address | Connaught House, Dublin, Ireland, D04 C5Y6 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 1,800 |
